The At its November 2022 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines for Human Use (EMA) Renewal recommended for Trastuzumab deruxtecan (Enhertu, Daiichi Sankyo Europe GmbH):
The antibody-drug conjugate directed against HER2 will also be indicated as monotherapy for the treatment of adult patients with advanced HER2-positive gastric adenocarcinoma or gastroesophageal junction who have previously received trastuzumab-based treatment.
So far, the conjugate has been used in unresectable or metastatic HER2-positive breast cancer.
This full text is unfortunately reserved for medical professionals
You have reached the maximum number of articles for unregistered visitors
Source — https://www.univadis.de/viewarticle/ema-empfiehlt-zulassungserweiterung-f%25C3%25BCr-trastuzumab-2022a10027bc